Key result
Subcutaneous low molecular weight heparin (CY 216) was more effective on phlebographic scores than continuous intravenous unfractionated heparin in 166 patients with deep vein thrombosis.
Why the study?
Does subcutaneous low molecular weight heparin (CY 216) improve phlebographic scores compared to intravenous unfractionated heparin in patients with deep vein thrombosis?
RCT (n=166)
Blinded evaluation of venograms
Randomized
Does subcutaneous low molecular weight heparin (CY 216) improve phlebographic scores compared to intravenous unfractionated heparin in patients with deep vein thrombosis?
Subcutaneous low molecular weight heparin (CY 216) is more effective than continuous intravenous unfractionated heparin for treating deep vein thrombosis, without increasing bleeding or embolic risks.
Answers are grounded in this paper and cite their sources.
Supports subcutaneous LMWH for DVT; extends RCT evidence favoring it over IV UFH.
The standard treatment of deep vein thrombosis is given by continuous intravenous infusion of unfractionated heparin. This entails hospitalisation, nursing care, immobility and repeated laboratory tests (e.g. activated partial thromboplastin time [APTT], platelet count). In addition approximately 10% of patients suffer major haemorrhages. The potential advantages of a low molecular weight heparin (CY 216) given subcutaneously were explored in a randomised trial with blind quantitative evaluation of venograms. The study included 166 patients and both "therapeutic efficacy" and "intention to-treat" analyses showed that subcutaneous CY 216 in fixed doses based only on body weight was more effective on the Arnesen and Marder phlebographic scores than continuous i.v. standard heparin with daily dose adjustment according to results of coagulation tests. There was no increase in the risks of pulmonary embolism, haemorrhage or clot extension.
No takes yet. Share an insight, caveat, or question.
Ninet et al. (1991) conducted an RCT in Deep vein thrombosis (n=166). Subcutaneous low molecular weight heparin (CY 216) vs. Continuous intravenous unfractionated heparin was evaluated on Arnesen and Marder phlebographic scores. Subcutaneous low molecular weight heparin (CY 216) was more effective on phlebographic scores than continuous intravenous unfractionated heparin in 166 patients with deep vein thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: